Imidazoline I2 receptor density increases with the malignancy of human gliomas

25Citations
Citations of this article
16Readers
Mendeley users who have this article in their library.

Abstract

Background: Current glioma grading schemes are limited by subjective histological criteria. Imidazoline I2 receptors are principally expressed on glial cells. Objective: To investigate the feasibility of using the measurement of imidazoline I2 receptor expression to differentiate glial tumours from other types of brain tumours and for grading the different gliomas. Methods: The specific binding of [3H]idazoxan to imidazoline I2 receptors was measured in homogenates from human gliomas of different grades. Results: The density of imidazoline I2 receptors was significantly greater in the three types of malignant glial tumours than in postmortem control brain or non-glial tumours. The increase in density correlated with the malignancy grade of the gliomas. No significant differences in affinity values were observed. Conclusion: These results suggest that the density of imidazoline I2 receptors may be a useful radioligand parameter for the differentiation of glial tumours from other types of brain tumours and for grading the different gliomas.

Cite

CITATION STYLE

APA

Callado, L. F., Martín-Gómez, J. I., Ruiz, J., Garibi, J. M., & Meana, J. J. (2004). Imidazoline I2 receptor density increases with the malignancy of human gliomas. Journal of Neurology, Neurosurgery and Psychiatry, 75(5), 785–787. https://doi.org/10.1136/jnnp.2003.020446

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free